New Zealand markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.2200-0.0100 (-0.81%)
At close: 04:00PM EDT
1.2100 -0.01 (-0.82%)
After hours: 07:55PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 64.31M
Enterprise value -7.27M
Trailing P/E 7.18
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.07
Price/book (mrq)1.17
Enterprise value/revenue -0.13
Enterprise value/EBITDA 0.77

Trading information

Stock price history

Beta (5Y monthly) 0.89
52-week change 3-38.07%
S&P500 52-week change 317.24%
52-week high 32.4100
52-week low 31.2000
50-day moving average 31.3933
200-day moving average 31.6107

Share statistics

Avg vol (3-month) 3355.25k
Avg vol (10-day) 3270.49k
Shares outstanding 552.72M
Implied shares outstanding 652.72M
Float 836.87M
% held by insiders 118.94%
% held by institutions 127.24%
Shares short (30 Aug 2023) 41.14M
Short ratio (30 Aug 2023) 42.24
Short % of float (30 Aug 2023) 42.66%
Short % of shares outstanding (30 Aug 2023) 42.17%
Shares short (prior month 30 Jul 2023) 41.17M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023

Profitability

Profit margin -18.59%
Operating margin (ttm)-24.42%

Management effectiveness

Return on assets (ttm)-10.19%
Return on equity (ttm)-22.24%

Income statement

Revenue (ttm)54.23M
Revenue per share (ttm)1.14
Quarterly revenue growth (yoy)36.30%
Gross profit (ttm)N/A
EBITDA -12.64M
Net income avi to common (ttm)-10.08M
Diluted EPS (ttm)0.1700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)77.69M
Total cash per share (mrq)1.47
Total debt (mrq)6.11M
Total debt/equity (mrq)11.15%
Current ratio (mrq)5.10
Book value per share (mrq)1.04

Cash flow statement

Operating cash flow (ttm)12.11M
Levered free cash flow (ttm)-228.12k